News

GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - ...
BioSpace1d
After Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
European Medicines Agency Supports Streamlined Development Pathway for GEO-MVA Vaccine Candidate via a Single Phase 3 ...
Equity Insider: Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research ...
The Globe and Mail19d
GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and ...
GeoVax’s development-stage continuous avian cell line process is anticipated to provide increased production of MVA-based vaccines, the ability to quickly respond to epidemics and pandemics ...
Wall Street Journal22d
GeoVax Labs Inc. Wt (GOVXW) Stock Price Today - WSJ
View the latest GeoVax Labs Inc. Wt (GOVXW) stock price, news, historical charts, analyst ratings and financial information from WSJ.
The Globe and Mail26d
GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
ATLANTA, GA - June 25, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, ...